This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eszlinger, M. Articles by Paschke, R. Search for Related Content PubMed PubMed Citation Articles by Eszlinger, M. Articles by Paschke, R.

Perspectives and Limitations of Microarray-Based Gene Expression Profiling of Thyroid Tumors

Markus Eszlinger, Knut Krohn, Aleksandra Kukulska, Barbara Jarzb and Ralf Paschke

III. Medical Department (M.E., K.K., R.P.), University of Leipzig, D-04103 Leipzig, Germany; Interdisciplinary Center for Clinical Research Leipzig (K.K.), D-04103 Leipzig, Germany; and Department of Nuclear Medicine and Endocrine Oncology (A.K., B.J.), Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, 44-100 Gliwice, Poland

Correspondence: Address all correspondence and requests for reprints to: R. Paschke, M.D., III. Medical Department, University of Leipzig, Ph.-Rosenthal-Str. 27, D-04103 Leipzig, Germany. E-mail: pasr{at}medizin.uni-leipzig.de

	Abstract

Top Abstract I. Introduction II. New Perspectives Generated... III. First Results,... IV. Future Developments References

 
Microarray technology has become a powerful tool to analyze the gene expression of tens of thousands of genes simultaneously. Microarray-based gene expression profiles are available for malignant thyroid tumors (i.e., follicular thyroid carcinoma, and papillary thyroid carcinoma), and for benign thyroid tumors (such as autonomously functioning thyroid nodules and cold thyroid nodules). In general, the two main foci of microarray investigations are improved understanding of the pathophysiology/molecular etiology of thyroid neoplasia and the detection of genetic markers that could improve the differential diagnosis of thyroid tumors. Their results revealed new features, not known from one-gene studies. Simultaneously, the increasing number of microarray analyses of different thyroid pathologies raises the demand to efficiently compare the data. However, the use of different microarray platforms complicates cross-analysis. In addition, there are other important differences between these studies: 1) some studies use intraindividual comparisons, whereas other studies perform interindividual comparisons; 2) the reference tissue is defined as strictly nonnodular healthy tissue or also contains benign lesions such as goiter, follicular adenoma, and hyperplastic nodules in some studies; and 3) the widely used Affymetrix GeneChip platform comprises several GeneChip generations that are only partially compatible. Moreover, the different studies are characterized by strong differences in data analysis methods, which vary from simple empiric filters to sophisticated statistic algorithms. Therefore, this review summarizes and compares the different published reports in the context of their study design. It also illustrates perspectives and solutions for data set integration and meta-analysis, as well as the possibilities to combine array analysis with other genetic approaches.

I. Introduction

A. Potential of the method

B. Methodological evolution

II. New Perspectives Generated by Gene Expression Profiling of Benign and Malignant Thyroid Tumors

A. Papillary thyroid carcinoma (PTC)

B. Follicular thyroid carcinoma (FTC)

C. Autonomously functioning thyroid nodules (AFTNs)

D. Cold thyroid nodules (CTNs)

E. Clues for the comparison and differential diagnosis of thyroid nodules, based on the microarray data

III. First Results, Possibilities, and Solutions for Data Set Integration and Meta-Analysis

A. Study design

B. Types and generations of microarrays (one-color systems vs. two-color systems) and GeneChip generations

C. Selection of reference tissue and intra- vs. interindividual comparisons

IV. Future Developments

A. Diagnostic implications

B. Genome analysis (SNP arrays, arrayCGH)

	I. Introduction

Top Abstract I. Introduction II. New Perspectives Generated... III. First Results,... IV. Future Developments References

 
A. Potential of the method
ALTHOUGH THE BASIC concept of "microarrays" was presented in the early 1990s, about 10 yr elapsed before microarray technology became a widely used tool to analyze gene expression of tens of thousands of genes simultaneously on high-density microarrays in a single experiment. Such gene expression data allow us to identify genes that are expressed in a given cell type at a particular time and under a particular condition, to identify key players or target genes in signaling pathways, to recognize new targets of drugs, to find molecular markers in disease diagnosis, or to investigate the genetic background of an individual’s response to environmental factors (1).

B. Methodological evolution
As the sequence of information for the whole human genome became available, life scientists were challenged with the task of measuring the expression levels on a global scale. For this purpose, cDNA library clones were spotted on large membrane sheets to hybridize radiolabeled cDNA pools (2) generated from total or purified mRNA. This made it possible to measure the signal intensity of hundreds of transcripts. These ancestors of microarrays called "macroarrays" were characterized by several difficulties; e.g., they were made of porous material, they were difficult to handle, and they often required radioactive labeling techniques. The elimination of these technical drawbacks by the introduction of new carrier materials (i.e., glass slides) and fluorescence-based signal detection in 1995, when the first real cDNA microarray was established (3), formed the basis for a broad application. Subsequently, new developments in automation, robotic spotting, photolithography, fluorescence-based detection, and bioinformatics led to a rapid growth in microarray usage. According to the length of spotted DNA fragments, all RNA expression arrays can be subdivided into two groups: 1) cDNA microarrays that use approximately 200- to 500-bp double-stranded DNA fragments, which are normally produced by PCR; and 2) oligonucleotide microarrays that use 25–70 bp of single stranded DNA. Both cDNA and oligonucleotide fragments are chemically attached to the glass slides. These arrays are traditionally used with a two-color detection system; i.e., RNA from sample and control is labeled with fluorescent Cy3 and Cy5 dyes and hybridized to the same array. Therefore, these two-color arrays produce a ratio indicating the differential expression between the sample and the control. In contrast to these microarrays that are characterized by a deposition of cDNA fragments or oligonucleotides on the slides, Fodor and co-workers (Affymetrix, Santa Clara, CA) (4, 5, 6, 7) pioneered the development of a new in situ synthesis technology that combines photolithography known from the semiconductor industry and chemical DNA synthesis. This technology enabled a further miniaturization of the assay and the manufacturing of high-density oligonucleotide microarrays (GeneChips): the current version of Affymetrix GeneChips (Human Genome U133 Plus 2.0) provides a comprehensive coverage of the transcribed human genome on a single array covering over 47,000 transcripts represented by more than 1 million distinct oligonucleotide entities that cover a 11-µm square on the array (called feature size). Moreover, in contrast to the two-color arrays, Affymetrix GeneChips use a standardized biotin-labeling protocol and produce an intensity signal allowing absolute quantification.

The power of microarray studies depends not only on the quality of array design and production but also on the statistic and bioinformatic approaches used to analyze the data. Indeed, the application of different mathematical algorithms can influence the outcome of microarray data analysis enormously, e.g., by different statistical powers to detect significant differentially expressed genes. Early studies and studies employing radioactively labeled macroarrays often used housekeeping genes for data normalization (8) or simple algorithms such as z-score transformation (9, 10). However, normalization to classical housekeeping genes such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ß-actin (ACTB) is of limited value and requires special attention because it cannot be excluded that these genes are regulated [e.g., whereas no regulation of these genes has been observed in AFTNs, they do show differential expression in TSH-stimulated primary thyroid epithelial cells (11)]. As an alternative, various preprocessing techniques have been developed: e.g., MAS5.0 (12), dChip (13), Robust Multichip Average (RMA) (14, 15), and GC-RMA (16). However, so far a clear recommendation for the best performing algorithm cannot be given (17). Similar to the high number of preprocessing algorithms, numerous methods of data analysis have been published. They can be classified as methods to detect differentially expressed genes and gene sets in a supervised manner (e.g., empirical filtering, statistic algorithms such as t test, F test), unsupervised cluster analysis (e.g., hierarchical clustering, self-organizing maps, k-mean clustering), and supervised sample classification [e.g., Recursive Feature Replacement (RFR) (18, 19), Prediction Analysis of Microarrays PAM (20)].

Because the introduction of microarrays has offered the possibility to investigate a multitude of parameters (i.e., genes) in a small number of samples (i.e., microarrays), this possibility introduced in parallel the most challenging problem of microarray analysis, which is the so-called "problem of multiple comparisons." Therefore, in up-to-date microarray studies, a correction for multiple comparisons [e.g., false discovery rate (FDR), Westfall-Young step-down permutation correction (21), and significance analysis of microarrays (22)] should be mandatory.

Hierarchical cluster analysis has become the most popular and most frequently used multivariate technique to analyze microarray data that results in a complete tree with leaves as individual patterns (genes or experiments) and the root as the convergence point of all branches. However, given enough genes, the genes will always cluster. Therefore, there is only minor scientific value in the fact that there are genes that behave in a similar way. Instead, the interpretation of a common clustering may be crucial. However, sometimes it seems that authors feel the urge to present their microarray results in the form of a cluster diagram, although such clusters are not always meaningful.

Because the conventional diagnosis of cancer is based on the morphological appearance of stained tissues whose analysis requires highly trained pathologists, the introduction of microarrays offered the hope that classification and prediction of cancer by means of their gene expression profiles could be more objective and accurate. Nevertheless, the problem of classification by microarrays is not simple; the genes that make it possible to predict the classes have to be identified from a large number of genes (in a relatively small number of samples). Moreover, it is important to identify which genes contribute most to the classification. For this purpose, several new computational methods have been developed. In addition to algorithms suggested by Golub et al. (23) and Hedenfalk et al. (24), a simple and well-performing approach based on nearest shrunken centroids has been proposed (20). At the moment, the reference method for classification problems in microarray studies are support vector machine (SVM) algorithms, and new promising supervised gene selection algorithms based on the SVM technique (25) [such as recursive feature elimination (26) and RFR (18, 19)] have been introduced.

An increasing number of studies have used microarrays in the field of thyroidology. These studies investigate (patho)-physiological questions or aim at elucidating the tumor’s molecular etiology (Table 1), whereas others look primarily for genetic markers that could improve the differential diagnosis of thyroid tumors. Both platforms, spotted cDNA and oligonucleotide microarrays with a two-color or radioactive detection, and in situ photolithographically synthesized oligonucleotide arrays with a one-color detection, have been used to analyze the gene expression profiles of malignant thyroid tumors [i.e., follicular thyroid carcinoma (FTC) (27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37) and papillary thyroid carcinoma (PTC) (31, 32, 33, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)], and benign thyroid tumors [such as autonomously functioning thyroid nodules (AFTNs) (8, 11, 48, 51, 52, 53) and cold thyroid nodules (CTNs) (8, 48, 51, 54)].

	II. New Perspectives Generated by Gene Expression Profiling of Benign and Malignant Thyroid Tumors

Top Abstract I. Introduction II. New Perspectives Generated... III. First Results,... IV. Future Developments References

For the adhesion-controlling PTC genes, it is well known that they participate in both invasion and metastasis and are involved in inflammation. Borrello et al. (56), who investigated the specific gene expression patterns of primary human thyrocytes transfected with the RET/PTC1 oncogene, could show that this oncogene activates the expression of a large set of genes involved in inflammation and tumor invasion, such as chemokines, matrix-degrading enzymes, and adhesion molecules. Interestingly, they also found this expression pattern in specimens of PTC harboring the RET/PTC rearrangement and pT4N1 presentation, which validates the in vivo relevance of their in vitro results. Therefore, and because PTCs are often associated with chronic inflammatory thyroiditis, the authors concluded that the inflammation-associated genes activated by RET/PTC1 most likely contribute to tumor progression and locoregional metastasis (56). This conclusion remains in some conflict with clinical data showing better outcome in PTC cases with concomitant lymphocytic infiltration (60). In the PTC gene expression profile, a very distinct expression pattern of immune response genes was observed, which follows in terms of intensity the pattern that is characteristic for the difference between tumor and normal tissue (44).

The molecular background of PTC was comprehensively investigated in a recent study of Melillo et al. (58). Using a broad methodology, they showed that the oncogenic proteins (i.e., RAS, BRAF, RET/PTC rearrangements) involved in the initiation of PTC signal within one cascade, namely the RAS-BRAF-MAPK-pathway. Nearly two thirds of the targets that are under the control of RET/PTC were shown to be regulated by the RAS-BRAF-MAPK pathway. This finding is supported by the gene expression study of Frattini et al. (43), which reveals similar global gene expression profiles of PTC harboring different genetic lesions. Although the molecular etiology of about 70% of all PTC is characterized by activating mutations or chromosomal rearrangements of BRAF, RET, or RAS (43, 61, 62, 63), a changed expression pattern of genes associated with the RAS-BRAF-MAPK pathway has not been described in human PTC microarray studies (31, 32, 33, 38, 40, 42, 43, 44, 45, 46). However, in a recent reanalysis of the data sets of Huang et al. (38) and Jarzab et al. (44) we did identify a significantly increased expression pattern for various genes of this pathway by GenMAPP analysis (48). Moreover, gene expression studies of papillary carcinoma cell lines harboring the RET/PTC3 rearrangement, a mutant HRAS (v-Ha-ras) or a mutant BRAF oncogene attributed the differential expression of numerous PTC markers, like LGALS3 and DUSP6, to the activation of the RAS-BRAF-MAPK pathway (58).

Although gene expression profiles of PTC with different genotypes (i.e., RAS or BRAF mutation, RET/PTC rearrangements) share a high similarity, they are not identical (Table 2). Melillo et al. (58) could show that a large number of genes are specifically modulated by only one or two of the three oncogenes (i.e., RET/PTC, RAS, and BRAF). Therefore, the three oncoproteins, which are part of a single signaling pathway, are each able to trigger specific signals in addition to the common ones. This conclusion is supported and widened by the gene expression profiling of Giordano et al. (46), who could show strong relationships not only between gene expression and PTC morphology, but also between the gene expression pattern and the occurrence of RET/PTC rearrangements and BRAF or RAS mutations. Therefore, it is very likely that the activation or interaction of/with additional/alternative signaling pathways forms the molecular basis of tumors and causes discrete mutation-specific phenotypic features (e.g., morphology).

Differences in the gene expression profile of PTC variants were indicated by Giordano et al. (46), who showed that PTCs of classic, follicular, and tall cell variants did cluster separately by principal component analysis. The difference between classic and tall cell variant was also described by Wreesmann et al. (47). On the other hand, the differences between the classic and follicular PTC variant are less visible (40), although some authors published lists of genes differentiating both variants (32).

The various groups specify different markers for the molecular diagnosis of PTC, such as SFTPB and CITED 1 (38), ADM (adrenomedullin), TROP2 (tumor-associated calcium signal transducer 2), and NRP2 (neuropilin 2) (40); the gene set of KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog), CDH1 (cadherin 1), LSM7 (LSM7 homolog, U6 small nuclear RNA associated), SYNGR2 (synaptogyrin 2), FAM13A1 (family with sequence similarity 13, member A1), IMPACT (Impact homolog) and four nameless genes (42); and a 20-gene classifier (44) as well as gene lists comprising hundreds of genes (33, 40). This issue will be addressed below.

B. Follicular thyroid carcinoma (FTC)
Gene expression profiles of FTC were analyzed in several microarray studies, with the aim to improve the molecular differentiation between FTC and follicular adenomas and to elucidate the molecular etiology of FTC further (27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37).

In an early investigation, Barden et al. (29) compared the gene expression profiles of FTC and follicular adenoma using Affymetrix GeneChips and found strikingly distinct gene expression patterns for both entities. They identified 105 differentially expressed genes between FTC and follicular adenoma including ADM, GPC1 (glypican 1), TGFA (TGF), MET and IGFBP3 (IGF binding protein 3) (up-regulated in FTC), and DIO1, CREM (cAMP-responsive element modulator), FBLN5 (fibulin 5), and MT1 (metallothionein 1) (down-regulated in FTC). An alternative approach of microarray analysis that aims at identifying the minimal number of discriminating genes appears more promising for diagnostic purposes and could also lead to further elucidation of the molecular etiology. Weber et al. (30) applied the linear discriminant analysis to their data set of FTC and benign thyroid samples to find the best combination of genes discriminating the different entities. Using this approach, they identified the combination of CCND2 (cyclin D2), PCSK2 (proprotein convertase subtilisin/kexin type 2), and PLAB (growth differentiation factor 15) that allowed accurate differentiation between benign and malignant follicular thyroid neoplasia with a high sensitivity and specificity. Cerutti et al. (71) have specified another set of genes, based on serial analysis of gene expression (SAGE) analysis, which comprised DDIT3 (DNA-damage-inducible transcript 3), ARG2 (arginase, type II), ITM1 (integral membrane protein 1), and C1orf24. Although these genes were primarily selected for diagnostic purposes (with the aim to differentiate between follicular adenomas and carcinomas), they should also be considered for their significance regarding the biology of FTC.

By a combination of microarray data and previously published loss of heterozygosity data of FTC and normal thyroid samples, Aldred et al. (27) identified five new putative tumor suppressor genes. Three of them belong to a set of most consistently down-regulated genes [CAV1 (caveolin 1), CAV2 (caveolin 2), and GDF10 (growth differentiation factor 10)], whereas GPC3 (glypican 3) and CHRDL (chordin-like 1) might be functionally related to GDF10. Although both caveolins are down-regulated in FTC, their molecular mechanisms of down-regulation remain unclear. Loss of heterozygosity was found in a subgroup of tumors, but the authors could not identify mutations in either gene, and furthermore, the methylation status of the caveolin-1 promoter did not correlate with the expression pattern (27). The investigation of GDF10, GPC3, and CHRDL revealed similar results. Moreover, GPC3 and CHRDL have also been shown to be down-regulated in AFTNs (52) and CTNs (54). Therefore, these genes most likely do not make it possible to distinguish between benign and malignant thyroid tumors.

Subsequent to the independent analysis of their PTC and FTC microarray data, Huang et al. (38) and Aldred et al. (27) combined their data sets and compared the gene expression profiles of FTC and PTC to understand better the similarities and differences between these two tumor types (31). They identified genes that are characterized by a differential expression between FTC and PTC [CST6 (cystatin E/M), DPYSL3 (dihydropyrimidinase-like 3), G0S2 (G0/G1switch 2), IGFBP6 (IGF binding protein 6), CITED1, CLDN10 (claudin 10), CAV1, and CAV2], and additional 28 genes including TG (thyroglobulin), TPO, GPC3, DUSP1, APOD (apolipoprotein D), MT1G (metallothionein 1G), and CRABP1 (cellular retinoic acid binding protein 1) that are characterized by a decreased expression in both entities, which might suggest a common origin of FTC and PTC. However, this conclusion might be overstated because TG, TPO, MT1G, and CRABP1 are characterized by an increased expression in AFTNs (52), which rather suggests a functional relevance for thyroid hormone production. In contrast, the decreased expression of GPC3 and APOD, which has also been shown in AFTNs (52) and CTNs (54), most likely reflects increased proliferation that is inherent to all tumor entities.

In addition to activating RAS mutations, which have been found in follicular neoplasms (72), a fusion oncogene between PAX8 and PPAR has been identified in up to 63% of FTC (73), but also in a number of follicular adenomas (74, 75, 76). However, the knowledge about the detailed molecular events by which PAX8-PPAR contributes to tumor development is so far limited (77). Therefore, to identify molecular signatures of FTC with and without the PAX8-PPAR fusion oncogene, Lui et al. (36) performed a gene expression profiling of both subtypes. In their study, Lui et al. could show a highly uniform expression profile in the FTC characterized by a PAX8-PPAR fusion oncogene that differed significantly from those of the FTC without the fusion oncogene. On the basis of these results, they reasoned that FTCs with a PAX8-PPAR fusion oncogene form a distinct biological entity within the FTC. Moreover, this conclusion is in line with other findings. French et al. (78) demonstrated distinct clinicopathological features in FTC with a PAX8-PPAR rearrangement. Nikiforova et al. (79) proposed two distinct pathways involved in the development of FTC (initiated by either RAS point mutations or PAX8-PPAR rearrangements). A gene expression profiling study of Lacroix et al. (34) also identified specific gene expression patterns associated with the PAX8-PPAR rearrangement. In addition, the assumption of a distinct PAX8-PPAR pathway is supported by a differential expression of signal transduction genes [e.g., increased: EPOR (erythropoietin receptor), ADCY9 (adenylate cyclase 9), EPAC (Rap guanine nucleotide exchange factor 3), and DUSP6; decreased: HINT1 (histidine triad nucleotide binding protein 1), RAP1GA1 (RAP1 GTPase activating protein), and CSNK2B (casein kinase 2)] and proliferation-associated genes [e.g., CTBP2 (C-terminal binding protein 2), FSCN1 (fascin homolog 1), and CCND1 (cyclin D1)] in FTC with a PAX8-PPAR rearrangement (36). Recently, Giordano et al. (28) studied the implications of the PAX8-PPAR fusion protein for the neoplastic mechanism of FTC by a comprehensive investigation of gene expression profiles of PAX8-PPAR-positive FTC in comparison to PAX8-PPAR-negative FTC, along with other common thyroid tumors such as follicular adenomas, oncocytic carcinomas, oncocytic adenomas, and papillary carcinomas. PAX8-PPAR-positive FTC could be identified by examining the microarray data for increased expression of PPAR (28). Moreover, principal component analysis of all follicular neoplasms revealed a separation of the PAX8-PPAR-positive FTC from the PAX8-PPAR-negative FTC and the follicular adenomas, suggesting that the PAX8-PPAR rearrangement is the predominant source of variation in gene expression within this set of tumors (28). Interestingly, in their study Giordano et al. (28) could show that the PAX8-PPAR fusion protein can function in a PPAR-like manner, although it also has transcriptional properties distinct from either PAX8 or PPAR. These findings are contrary to the original description of the PAX8-PPAR fusion protein (73). Kroll et al. (73) showed that the fusion protein does not activate PPAR-responsive promoters, but functions as a dominant-negative inhibitor of PPAR-induced reporter gene activation. Therefore, the inhibition of endogenous PPAR is said to be an important mechanism by which the PAX8-PPAR fusion protein causes FTC. However, due to Giordano’s findings (28), the concept that the PAX8-PPAR fusion protein contributes to follicular carcinoma by antagonizing endogenous PPAR needs reevaluation. Advanced bioinformatic analysis of Giordano’s data revealed potential roles of several metabolic pathways in the oncogenic action of the fusion protein. An enrichment of the PAX8-PPAR expression signature was observed in pathways related to fatty acid oxidation and metabolism, and to amino acid and carbohydrate metabolism. These results are striking because PPAR regulates adipogenesis and glucose metabolism.

C. Autonomously functioning thyroid nodules (AFTNs)
In an early study using membrane arrays and radioactively labeled cDNA probes, we could show a down-regulation of several signal-transducing components such as IGF-II, the platelet-derived growth factor receptor (PDGFR) and the type III TGF-ß receptor (TGFBR3) in AFTNs and CTNs, which suggested a disturbed signaling system (8). In a recent study, we confirmed these findings. The TGF-ß signaling cascade is particularly characterized by strong changes in its pattern of gene expression in AFTNs when compared with their normal surrounding tissues (ST): the TGFBR3, SMAD 1, 3, and 4, as well as p300, a transcriptional coactivator, showed a decreased expression in AFTNs, whereas the inhibitory SMAD 6 and 7 showed an increased expression in AFTNs. Moreover, a decreased expression of TGFBR3 and TGFB1 could also be shown at the protein level (52, 80). These findings suggest an inactivation of TGF-ß signaling in AFTNs due to a constitutively activated TSH receptor (TSHR) (e.g., resulting from TSHR mutations) (52).

Because the molecular etiology of AFTNs is mainly characterized by a constitutively activated TSHR-cAMP-pathway, we compared the gene expression profiles of TSH-stimulated primary thyroid epithelial cells (51). Because these data also showed significant differences in the gene expression profiles of the TGF-ß signaling cascade, the findings in the AFTNs are most likely due to the constitutively activated cAMP cascade. This is further supported by investigations of TSH-stimulated porcine thyroid follicles ex vivo (81) showing a decreased TGFB1 mRNA expression. Furthermore, in the context of an increased ß-arrestin 2 expression in AFTNs (82), findings of a ß-arrestin 2 mediated endocytosis of the TGFBR3 and a subsequent down-regulation of its signaling by Chen et al. (83) support and further elucidate this interpretation. It has been suggested that a down-regulation of lymphocyte and macrophage-specific genes (52, 53) might reflect a different cellular composition of the AFTNs with a lack of lymphocytes and discussed by Wattel et al. (53). However, the specific expression patterns of TGF-ß signaling-associated genes in thyrocytes are not influenced by the different cellular composition and could be reproduced in TSH-stimulated primary thyroid epithelial cells (51).

Interestingly, two independent studies using different microarray platforms (i.e., spotted glass slides and Affymetrix GeneChips) and different methods of data analysis consistently show an increased expression of thyroid-specific genes such as TPO and DIO1, as well as collagen (type IX, 3), different metallothioneins, and sialyltransferase (SIAT)1 in AFTNs (52, 53). The stringent and prominent SIAT1 expression pattern that we found in our microarray study of AFTNs (52) prompted us to investigate one of its possible functional relevances further. Subsequent studies characterized a new aspect of posttranslational modification of the TSHR. In cell culture experiments, we demonstrated for the first time that the transfer of sialic acid directly affects TSHR signaling because it improves and prolongs the cell-surface expression of the TSHR (84). Furthermore, microarray investigations of AFTNs and TSH-stimulated primary thyroid cells illustrate a remarkable induction or activation of negative feedback mechanisms such as an up-regulation of phosphodiesterases (11, 51, 53), which is in line with previous findings of Persani et al. (85). Moreover, the presence of negative feedback mechanisms in AFTNs is further supported by an increased expression of G protein-coupled receptor kinases (GRK) in AFTNs and their ability to desensitize the TSHR as shown in in vitro experiments (86). Interestingly, whereas microarray studies of TSH-stimulated primary thyroid cell cultures reveal an increased expression of the regulator of G protein signaling (RGS) 2 (11, 51), which has been shown to reduce the TSHR signaling via inositol-3-phosphate (87), RGS2 is characterized by a decreased expression in AFTNs (11, 51, 88). Such a difference can most likely be explained by defects in the RGS regulation pathway or by additional counter-regulatory mechanisms that occur only in the chronically proliferating AFTNs. Furthermore, in TSH-stimulated primary thyroid cell cultures, an increased expression of CREM, which acts as an repressor of cAMP-induced genes (89), could be observed, although this was not observed by microarray studies of AFTNs (11, 51). These findings demonstrate that the additional investigation of a compatible cell model (e.g., TSH-stimulated primary thyroid epithelial cells) may confirm and further define and/or explain specific gene expression patterns (e.g., TGF-ß signaling cascade) detected in tissue samples (e.g., AFTNs). However, it is obvious that the gene expression profile of the cell model itself can only depict a part of the complex situation present in the tissue samples.

The comparison of the gene expression patterns of AFTNs harboring a somatic TSHR mutation and TSHR mutation-negative AFTNs (52) indicated a number of signal transduction genes [e.g., p21/Cdc42/Rac1-activated kinase (PAK)1 and 2, RGS4 and -6, Janus kinase (JAK)1, and G protein-coupled receptor kinase (GRK)2] which are characterized by a different expression pattern between these two subgroups of AFTNs. These findings indicate strong differences in the signal transduction of AFTNs caused by constitutively activating mutations in the TSHR compared with AFTNs without TSHR mutations and could thus give a lead for the elucidation of their molecular etiology.

Taken together, the global analysis of gene expression profiles of AFTNs showed both an inactivation of TGF-ß signaling and a remarkable induction or activation of negative feedback mechanisms in the AFTNs, which could also be confirmed in a compatible cell model in TSH-stimulated primary thyroid epithelial cells. Moreover, the prominent SIAT1 expression pattern in AFTNs provided the basis for the characterization of a new aspect of posttranslational modification of the TSHR.

D. Cold thyroid nodules (CTNs)
Several microarray studies, which were performed with the aim to identify novel diagnostic and clinical markers for differentiated thyroid tumors, used benign thyroid nodules, histologically classified as follicular adenoma or hyperplastic nodules, for comparison with PTC and FTC (29, 30, 32, 33, 35, 37, 40, 42, 49, 90). However, with respect to their function, histologically benign thyroid nodules can be further distinguished as AFTNs or CTNs or less often as so-called warm nodules, which do not show detectable differences to the surrounding thyroid tissue by scintigraphy. CTNs constitute the most abundant thyroid nodular lesion with a prevalence of about 80% of all palpable thyroid nodules (91). In contrast to AFTNs (described in Section II.C), the current knowledge concerning their molecular etiology is very limited. Nevertheless, there is only one study that investigated the array-based gene expression profiles of CTNs classified by scintigraphy (54).

In an early study we could show a down-regulation of several signal transducing components both in AFTNs and CTNs, which seemed to reflect a disturbed signaling system (8). These similarities in the gene expression patterns of AFTNs and CTNs might be attributable to a common property of both benign tumor entities, e.g., increased proliferation (92, 93). To gain a higher resolution that might help to identify specific signaling cascades involved in nodular development, we subsequently compared gene expression profiles of 22 CTNs to their normal surrounding tissue using the U95A Affymetrix GeneChip (54). On the basis of the high number of investigated genes (approximately 10,000 full-length genes) and an improved statistical analysis that made it possible to analyze the significance of differential gene expression within gene sets (e.g., signaling cascades), the molecular pattern of the increased proliferation in CTNs (93) could be further defined. Regulation of gene expression was most consistent for a number of histone mRNAs and gene sets containing cell cycle-associated genes, like cyclin D1, cyclin H/cyclin-dependent kinase (CDK) 7, and cyclin B. Furthermore, these expression data also revealed that contrary to PTCs, altered expression of components belonging to the RAS-MAPK cascade is of minor importance for the development of CTNs because gene sets representing this pathway did not show differential expression in comparison to the surrounding normal tissue. This is in line with findings of Esapa et al. (94), who showed that a general relevance of RAS mutations for the development of follicular adenoma is unlikely. Moreover, these results are supported by findings of Krohn et al. (95) and a recent in vitro study indicating that the dedifferentiated phenotype of CTNs is unlikely to be the result of an activated RAS signaling (96).

Interestingly, the gene set analysis also revealed a significantly altered expression pattern in the group of G protein signaling molecules, which is mainly based on a differential expression of several protein kinase C (PKC) isoforms and an increased expression of the G_q protein. This expression pattern is especially interesting because it has been shown that thyroid cells undergoing a long-term PKC stimulation are characterized by a general loss of thyroid-specific functions (e.g., loss of iodide transport and thyroglobulin iodination), which is reminiscent of CTNs (97, 98, 99, 100, 101).

The up-regulation of cell cycle genes in the gene expression profile of CTNs (54) is so distinct that it may be used for the differential molecular diagnosis of these tumors, as shown by RFR algorithm (44). Mainly genes related to proliferation and growth processes were included into a 20-gene molecular classifier (e.g., cyclin-dependent kinase inhibitor 1C, histone 1 H2be, and histone 2 H2aa). Furthermore, the CTN classifier contains genes considered as cancer specific, such as the fibroblast growth factor receptor 1 (FGFR1) found down-regulated by Chevillard et al. (32) in the follicular variant of PTC in comparison with the classic variant, TLE4 (Transducin-like enhancer protein 4), described by Aldred et al. (27) as down-regulated in FTC, and TUSC3 (tumor suppressor candidate 3) overexpressed in PTC (38). In contrast to AFTNs, the CTN multigene signature was also found in some PTC, which could be explained by the partly dedifferentiated and proliferating phenotype that is common to both entities.

Several studies provide evidence that differentiated functions of thyrocytes and of iodide metabolism can be reinduced by retinoic acid (102, 103, 104). Therefore, the significantly changed expression pattern of CRABP1 in CTNs is of special interest (54). CRABP1 encodes a high-affinity cellular retinoic acid binding protein that regulates the availability of retinoic acid for its nuclear receptors and is also involved in retinoic acid catabolism (105). Therefore, the decreased mRNA expression and the decreased protein expression of CRABP1 in CTNs might also impact on the partly dedifferentiated and hypofunctioning phenotype of this tumor entity. Our recent findings showing an increased expression of CRABP1 in AFTNs in comparison to their normal surrounding tissue support this assumption (unpublished observation). Moreover, because a decreased CRABP1 expression has also been shown in PTC (38) and FTC (27) in addition to CTNs, a reduced expression of CRABP1 most likely reflects an early dedifferentiating event in the pathogenesis of thyroid tumors.

Overall, in addition to the interesting finding of decreased CRABP1 expression, gene expression profiling of CTNs allowed identification of the molecular pattern of their increased proliferation that is characterized by a differential expression of several cell cycle-associated genes. Moreover, whereas the RAS-MAPK cascade is most likely of minor importance for the development of CTNs, the gene expression patterns of the G_q-PKC pathway suggest further investigations to define its relevance in relation to the dedifferentiated phenotype of CTNs.

E. Clues for the comparison and differential diagnosis of thyroid nodules, based on the microarray data
Despite the fact that microarray studies revealed very distinct changes in the expression of certain genes, none of the several genes identified by array studies as differentially regulated was proven to be an ideal single marker of PTC (106, 107, 108, 109, 110, 111, 112, 113, 114, 115). For example, DPP4 (dipeptidyl-peptidase 4), which was indicated by Huang et al. (38) and later shown by Jarzab et al. (44) to be the most up-regulated gene in PTC, did not clearly differentiate between PTC and benign tissue (116). Also, oncofibronectin, galectin 3, and other proposed markers did not work properly in a single gene context (117, 118, 119, 120, 121). Moreover, the different multigene classifiers proposed by various authors showed only a minor overlap of the respective markers included. In fact, such a comparison requires a systematic bioinformatic approach. Such analysis has been performed in some types of cancer (122) but is not available for thyroid cancer.

In a study comprising 62 samples of PTC, follicular variant of PTC, FTC, medullary thyroid carcinoma, and follicular adenomas/hyperplastic nodules, a set of 662 differentially expressed genes was identified that discriminates between benign and malignant thyroid tumors (33). The discriminating gene set contained both known cancer-associated genes (e.g., LGALS3, TIMP, TGFA, ADM, MET, and FN1) and previously unidentified genes. However, such large gene lists are not applicable for diagnostic purposes. Thus, approaches to limit the number of genes in an identifier have been undertaken. The aim of the study of Jarzab et al. (44) was not to list genes with the largest fold-changes, but rather to specify the most powerful set of genes that discriminate PTC and benign tissue. This gene set was selected not by univariate approaches but by complementation of the genes, by a RFR algorithm. Interestingly, the classifier does not contain many known genes found in other approaches like FN1 or TIMP, whereas some other genes previously known for their up-regulation in PTC (e.g., DPP4, SERPINA1, LGALS3, and MET) were included (Fig. 1). Within the classifier there were some new genes, previously not described in PTC [e.g., EVA1 (epithelial V-like antigen 1), and LPR4 (transmembrane 6 superfamily member 2)] or not evaluated in a diagnostic context (retinoid X receptor, , RXRG), as well as genes exhibiting less distinct changes in expression (e.g., gap junction protein, ß3, GJB3). The goal of this approach was not to obtain 20 genes showing a correlated change in expression between tumor and benign tissue but to generate complementary information from a selected set of genes. The idea of using gene interactions to improve classification accuracy can be explained with the simplest example of a two-gene linear interaction (Fig. 2). Within the shown data set of papillary thyroid cancers and normal/benign thyroid tissues, there are samples that cannot be classified by single markers, but their class could be predicted by a combination of them. However, two genes cannot classify all samples, and it is necessary to base the classification on a larger number of genes, usually five to 20.

View larger version (61K): [in this window] [in a new window]   FIG. 1. The 20-gene PTC classifier obtained by RFR [the name RFR-20 refers to the number of genes included in the classifier (44 )] performs very well to differentiate between tumors (red bar) and normal tissues (green bar). The intensity of the color refers to the intensity of gene expression; red refers to the up-regulation, and green refers to the down-regulation. However, only some genes (e.g., dipeptidylpeptidase 4, DPP4, to a lesser extent cadherin P, CDH3, and 1-antitrypsin, SERPINA 1) show a stable and very distinct difference in expression between both types of tissues. Other included genes (e.g., MET proto-oncogene, represented here by two different probe sets) give slightly different results. Also RXRG or galectin 3, LGALS3, are overexpressed only in a subset of PTC and, in the case of lack of overexpression, the information is completed by the expression of other genes.

View larger version (21K): [in this window] [in a new window]   FIG. 2. Classification of thyroid samples into two classes (papillary thyroid cancer and normal/benign thyroid), based on gene expression data for two transcripts, SERPINA1 and MET. Class prediction for sample ptc_t342 is correct only when based on expression of MET, whereas for ptc_t337 only SERPINA1 classifies this sample correctly. Taken together, these two markers make it possible to classify both samples properly. For the other two samples (ptc_t334 and 345), separation from normal samples based on these two genes is impossible, and further genes have to be included.

A more formal analysis of the accuracy of molecular diagnosis of PTC was also conducted with SVMs (K. Fujarewicz, M. Jarzab, M. Eszlinger, K. Krohn, R. Paschke, M. Oczko-Wojciechowska, M. Wiench, A. Kukulska, B. Jarzab, and A. Swierniak, manuscript in preparation). It proved that 98% of accuracy may be achieved with 95% confidence and limits the range between 95 and 100%. The lower limit of the 95% confidence interval reached 95% already with classifiers composed of only five genes. In this context, it is advisable to proceed with molecular classifiers composed of at least six genes. It is more than a simple coincidence that Mazzanti et al. (42) succeeded to differentiate their PTC samples from benign samples by a gene set of six genes and that another molecular classifier proposed for PTC on the basis of microarray data and published recently also consists of six genes (123).

Tumors and tissues often consist of more than one type of cells that might contribute differently to the measured expression of a given gene (124). The resulting problem of data interpretation in such a complex situation can be solved in different ways. Before the microarray experiment is performed, specific cell types can be isolated by microdissection. Alternatively, after microarray hybridization the expression of specific genes can be localized by in situ hybridization. Venet et al. (124) suggest a mathematic algorithm to separate samples consisting of different cell types. We prefer to include at least 10–20 genes into the classifier, both tumor markers and stromal cell markers. Still, at this number of genes, the conversion to a multi-quantitative PCR approach is feasible (125). Others prefer a wider minimalization, mainly because they intend to perform immunohistochemic identification. Weber et al. (30) have proposed a three-gene classifier for differentiation of follicular tumors, and Cerutti et al. (71) included four genes for the same purpose. These proposed marker sets should be reinvestigated in fine-needle aspiration (FNA) biopsies (FNABs) for their applicability to FNAB diagnosis.

	III. First Results, Possibilities, and Solutions for Data Set Integration and Meta-Analysis

Top Abstract I. Introduction II. New Perspectives Generated... III. First Results,... IV. Future Developments References

 
A. Study design
The diverse reports investigating the gene expression profiles of both benign and malignant thyroid tumors show a highly variable study design. In addition to the use of different microarray platforms, such as Affymetrix GeneChips and spotted oligo or cDNA arrays, there are important methodological differences between these reports with respect to: 1) GeneChip generation [e.g., U95A(v2) and U133A]; 2) reference tissue; and 3) the kind of array comparisons (Fig. 3). In addition, the diversity of the different studies is further increased by a large variety of applied algorithms for data preprocessing and data analysis. Although early studies and studies employing radioactively labeled macroarrays used housekeeping genes for data normalization (8) or simple algorithms such as z-score transformation (9, 10), the introduction of high-density microarrays such as the Affymetrix GeneChips goes along with the development of a number of much more sophisticated preprocessing algorithms (e.g., MAS5, RMA, GC-RMA) that integrate information from up to 18 pairs of oligonucleotides (collectively known as a probe set) into a single expression value per RNA transcript. Furthermore, the analysis of the preprocessed expression values allows the application of a variety of mathematical procedures. These start with simple filtering to identify differentially expressed genes at the low end and comprise statistical procedures adjusting for multiple testing (e.g., FDR, permutation procedures according to Westfall-Young, or significance analysis of microarrays), cluster analysis, and supervised learning techniques (e.g., SVMs with RFR) at the high end. It is therefore necessary to compare the results of microarray studies in the context of the complexity of their generation, which does not mean that the more complex analysis ensures more meaningful results.

View larger version (24K): [in this window] [in a new window]   FIG. 3. Methodological heterogeneity of microarray studies investigating the gene expression profiles of thyroid tumors.

C. Selection of reference tissue and intra- vs. interindividual comparisons
Some microarray studies of thyroid tumors tried to answer (patho-) physiological questions or aimed to elucidate the molecular etiology of the tumor, whereas others looked primarily for genetic markers that could improve the differential diagnosis of thyroid tumors. Because of these different questions to be answered by the microarray experiments, the selection of the reference tissues and the way of comparing the expression data varied significantly. In some studies, intraindividual comparisons were performed, whereas other studies performed interindividual comparisons. Furthermore, in some studies the reference tissue was defined as strictly nonnodular healthy tissue (8, 32, 34, 37, 38, 44, 45, 46, 48, 51, 52, 54), whereas it also comprised benign lesions such as goiter, follicular adenoma, and hyperplastic nodules in other studies (29, 30, 32, 33, 40, 42, 90). Moreover, there are differences in the nomenclature of benign tumors: whereas we prefer a nomenclature that is based on the function of the benign tumors (AFTNs, CTNs), other reports base their nomenclature on the histological morphology of the tumors (follicular adenoma, hyperplastic nodules). Therefore, in the case of comparing different microarray studies or performing a meta-analysis, it is mandatory to keep these characteristics of the different benign tumors in mind. Otherwise, discrepant and misleading results are preprogrammed.

Not only do advanced analyses such as comparison and meta-analysis of microarray studies require knowledge concerning the selection of the reference tissues and the type of comparison (i.e., intra- or interindividual comparisons). In a recent study, we addressed the relevance of paired (intraindividual) vs. unpaired (interindividual) data sets (48). The comparison of paired and unpaired PTC data sets clearly indicated a higher quality of paired data sets. Despite the fact that the paired data sets were hybridized to different GeneChip generations, the paired data sets showed more similarities in their gene expression profiles than the paired and the unpaired data sets that were hybridized to the same GeneChip generation and were generated in the same laboratory under identical conditions (however, there were some differences in the number of samples, which could also be relevant). The GenMAPP analysis of the paired PTC data sets showed significant differences in the expression pattern of the MAPK cascade, whereas the unpaired data set provided no indications for this alteration (48). Taken together, because intraindividual comparisons share more similarities even across GeneChip generations than intra- and interindividual comparisons using the same microarray generation, the elimination of the "individual background" by intraindividual comparisons seems mandatory, especially in studies whose objective is the identification of subtle differences, e.g., to elucidate the etiology of a specific pathology. In contrast, in studies looking for diagnostic markers of malignant tumors such as follicular and PTC, the variability of reference tissues might be of less importance; on the contrary, it may help to find out more robust cancer markers.

Furthermore, gene expression of thyroid tissue that is considered normal with regard to tumor characteristics could vary considerable. Bruno et al. (133) demonstrated differences in the expression of the sodium iodide symporter (SLC5A5) and the iodide transporter (SLC5A8) between thyroid tissue stimulated with low and normal serum TSH levels. Because the identification of differentially regulated genes critically depends on the type or metabolic status of the reference tissue as described above, we recently focused on differences in the gene expression patterns of the so-called "normal" surrounding tissues of AFTNs and CTNs (134). Principal component analysis and hierarchical clustering showed a distinct separation of the two subgroups, and statistical analysis revealed a significantly changed expression pattern of more than 300 genes (FDR < 1%). Among them, a decreased expression of thyroid-specific genes such as TSHR, TPO, and PAX8 in the ST of AFTNs could be shown. Moreover, in the ST of AFTNs, a correlation between the presurgical TSH levels and the gene expression of DIO1, TPO, SIAT1, and the G_i-protein 1 (GNAI1) could be observed (r > 0.7; P < 0.01). These data show strong differences in the gene expression patterns of so-called normal thyroid tissues, which can be attributed to their different TSH exposure. Therefore, a careful selection of the normal reference tissue by presurgical assessment of the TSH levels and scintigraphy in iodine-deficient areas should be performed in studies investigating the gene expression patterns of thyroid tumors.

	IV. Future Developments

Top Abstract I. Introduction II. New Perspectives Generated... III. First Results,... IV. Future Developments References

 
A. Diagnostic implications
The primary goal of the evaluation of patients with nodular thyroid disease is the exclusion of thyroid malignancy. However, the identification and differentiation of rarely occurring thyroid cancer from frequently occurring benign nodular thyroid disease is challenging. Although FNA cytology (FNAC) represents the most sensitive and specific tool for the differential diagnosis of thyroid malignancy, there are important limitations. Although 75% of FNACs reveal a benign lesion and 5% a malignant lesion, up to 20% of FNACs reveal follicular neoplasia for which surgery is the only method to differentiate between follicular adenoma, follicular carcinoma, and the follicular variant of papillary carcinoma (135). Therefore, especially in the case of FNAC showing follicular neoplasia, markers would be helpful to discriminate in particular between follicular carcinoma and follicular adenoma. Up to now, many markers have been screened and evaluated, e.g., LGALS3, hemoglobin, epsilon 1 (HBE1), keratin 19 (CK19), but also TPO, as well as genes related to initiation of transformation, like PAX8/PPAR rearrangements and BRAF mutations (136, 137, 138, 139). Although none of them are applicable to routine diagnostics so far, there is progress in molecular testing of fine-needle aspirates that may improve preoperative diagnosis. Most promising techniques are based on the detection of tumor-specific mutations (e.g., BRAF mutations, RET/PTC rearrangements) in the FNA material (140, 141, 142, 143). These methods are characterized by a high specificity and easy detection of the mutations in genomic DNA. However, because not all FTCs and PTCs are characterized by the currently known mutations in BRAF or RET/PTC rearrangements or PAX8/PPAR rearrangements, these methods are limited. Thus, the nearly genomewide microarray investigations of both benign and malignant thyroid tumors and the comparison of these different studies may help to identify additional potentially useful markers. Although data from microarray investigations suggest that this technology has the sensitivity and specificity needed for a screening tool and as an adjunct to clinical pathological diagnosis in the future (33, 39), currently the amount and the quality of the RNA available from FNAs is limiting such an analysis in routine diagnosis. Therefore, an assay based on a limited number of differentiating genes, identified by sophisticated algorithms in comparative studies, appears to be more promising for FNAB application (30, 44). However, in contrast to the analysis of tumor-specific mutations, this approach of quantitatively measuring RNA markers is more susceptible to potential limitations of FNA such as limited and variable numbers of follicular cells obtained in each biopsy and the potential contamination by other cell types such as activated lymphocytes in patients with lymphocytic thyroiditis. Therefore, a correction for mRNA yield (e.g., by measuring a housekeeping gene like ß-actin) and thyroid specificity of mRNA extracted from a FNA sample (e.g., by measuring a thyroid-specific gene like TG) seems mandatory. Nevertheless, the identification of genes or gene groups that correlate with nodular growth, thyroid dedifferentiation, or malignancy would make it possible to improve both diagnostics and therapy of thyroid nodular disease.

B. Genome analysis (SNP arrays, arrayCGH)
Up to now, the use of microarrays has mainly focused on the investigation of the transcriptome. However, advances in the microarray technology opened a wide range of new applications. The introduction of the Affymetrix GeneChip Mapping Arrays enables genotyping of up to 500,000 single nucleotide polymorphisms (SNPs) with an average distance between SNPs of 5.8 kb, which makes it possible to conduct large-scale linkage analyses, association studies, and copy number studies. This methodological development will also influence the genetic analysis of thyroid pathologies. In addition to a lack of iodine as the most prevalent factor for goiter development, familial clustering of goiters and the female predominance of goiters suggest a genetic background (144, 145). Actually, linkage analysis revealed two candidate regions, the multinodular goiter 1 locus and the Xp22 locus (146, 147, 148). A genomewide scan to detect susceptibility loci that predispose for euthyroid goiter using 450 microsatellite markers indicated genetic heterogeneity (149, 150). Therefore, linkage studies using SNP arrays will be an important adjunct to identify new susceptibility loci in an efficient way.

Comparative genomic hybridization (CGH) made a significant impact on cancer cytogenetics. It provides the possibility to detect chromosomal copy number changes in cells, tissue samples, and formalin-fixed paraffin-embedded material. However, CGH to metaphase chromosomes provides only a limited resolution of 5–10 Mb for the detection of copy-number losses and gains, 2 Mb for amplifications, and the analysis requires a high level of cytogenetic expertise. The introduction of microarray-based CGH (arrayCGH) with a higher resolution could circumvent these limitations, thus making a broader application possible. Because classic CGH revealed several chromosomal imbalances in follicular thyroid adenoma, FTC, and the follicular variant of PTC (151, 152, 153, 154), the investigation of thyroid tumors by microarray-based CGH might further resolve the pattern of these chromosomal aberrations or of the array expression patterns and might help to identify and specify the molecular etiology of thyroid tumors.

Additional new applications of microarray technology have been reported showing the high potential of this platform, e.g., the combination of chromatin immunoprecipitation (ChIP) with hybridization of microarrays (ChIP-on-chip), which is a powerful way to explore sites of DNA-protein interaction across the whole genome, and the analysis of the methylation status of CpG islands in promoter regions. On the basis of these high resolution techniques, new genes involved in diseases as well as mechanistic aspects of diseases are likely to be discovered.

	Footnotes

 
Disclosure Statement: M.E., K.K., A.K., and R.P. have nothing to declare. B.J. consults for Genzyme and received lecture fees from Novartis.

First Published Online March 12, 2007

Abbreviations: AFTN, Autonomously functioning thyroid nodule; CGH, comparative genomic hybridization; CTN, cold thyroid nodule; FDR, false discovery rate; FNA, fine-needle aspiration; FNAB, FNA biopsy; FNAC, FNA cytology; FTC, follicular thyroid carcinoma; PKC, protein kinase C; PTC, papillary thyroid carcinoma; RFR, recursive feature replacement; RGS, regulator of G protein signaling; SNP, single nucleotide polymorphism; ST, surrounding tissues; SVM, support vector machine; TSHR, TSH receptor.

	References

Top Abstract I. Introduction II. New Perspectives Generated... III. First Results,... IV. Future Developments References

 

1. Gershon D 2002 Microarray technology: an array of opportunities. Nature 416:885–891[CrossRef][Medline]
2. Gress TM, Hoheisel JD, Lennon GG, Zehetner G, Lehrach H 1992 Hybridization fingerprinting of high-density cDNA-library arrays with cDNA pools derived from whole tissues. Mamm Genome 3:609–619[CrossRef][Medline]
3. Schena M, Shalon D, Davis RW, Brown PO 1995 Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270:467–470[Abstract/Free Full Text]
4. Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D 1991 Light-directed, spatially addressable parallel chemical synthesis. Science 251:767–773[Abstract/Free Full Text]
5. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL 1996 Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14:1675–1680[CrossRef][Medline]
6. Chee M, Yang R, Hubbell E, Berno A, Huang XC, Stern D, Winkler J, Lockhart DJ, Morris MS, Fodor SP 1996 Accessing genetic information with high-density DNA arrays. Science 274:610–614[Abstract/Free Full Text]
7. Wodicka L, Dong H, Mittmann M, Ho MH, Lockhart DJ 1997 Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat Biotechnol 15:1359–1367[CrossRef][Medline]
8. Eszlinger M, Krohn K, Paschke R 2001 Complementary DNA expression array analysis suggests a lower expression of signal transduction proteins and receptors in cold and hot thyroid nodules. J Clin Endocrinol Metab 86:4834–4842[Abstract/Free Full Text]
9. Cheadle C, Vawter MP, Freed WJ, Becker KG 2003 Analysis of microarray data using Z score transformation. J Mol Diagn 5:73–81[Abstract/Free Full Text]
10. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood III WH, Donovan DM, Webster M, Freed WJ, Becker KG 2001 Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res Bull 55:641–650[CrossRef][Medline]
11. van Staveren WC, Solis DW, Delys L, Venet D, Cappello M, Andry G, Dumont JE, Libert F, Detours V, Maenhaut C 2006 From the cover: gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. Proc Natl Acad Sci USA 103:413–418[Abstract/Free Full Text]
12. Hubbell E, Liu WM, Mei R 2002 Robust estimators for expression analysis. Bioinformatics 18:1585–1592[Abstract/Free Full Text]
13. Li C, Wong WH 2001 Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 98:31–36[Abstract/Free Full Text]
14. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP 2003 Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249–264[Abstract]
15. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP 2003 Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31:e15
16. Wu Z, Irizarry RA, Gentleman R, Murillo FM, Spencer F 2003 A model-based background adjustment for oligonucleotide expression arrays. Technical report. Baltimore, MD: Johns Hopkins University, Department of Biostatistics Working Papers
17. Shedden K, Chen W, Kuick R, Ghosh D, Macdonald J, Cho KR, Giordano TJ, Gruber SB, Fearon ER, Taylor JM, Hanash S 2005 Comparison of seven methods for producing Affymetrix expression scores based on false discovery rates in disease profiling data. BMC Bioinformatics 6:26[CrossRef][Medline]
18. Fujarewicz K, Wiench M 2003 Selecting differentially expressed genes for colon tumor classification. Int J Applied Math Comp Science 13:327–335
19. Fujarewicz K, Kimmel M, Rzeszowska-Wolny J, Swierniak A 2003 A note on classification of gene expression data using support vector machines. J Biol Systems 11:43–56[CrossRef]
20. Tibshirani R, Hastie T, Narasimhan B, Chu G 2002 Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99:6567–6572[Abstract/Free Full Text]
21. Westfall PH, Young SS 1993 Resampling-based multiple testing: examples and methods for multiple P-value adjustment. New York: John Wiley & Sons
22. Tusher VG, Tibshirani R, Chu G 2001 Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116–5121[Abstract/Free Full Text]
23. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES 1999 Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531–537[Abstract/Free Full Text]
24. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J 2001 Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:539–548[Abstract/Free Full Text]
25. Vapnik V 1995 The nature of statistical learning theory. New York: Springer-Verlag
26. Guyon I, Weston J, Barnhill S, Vapnik V 2002 Gene selection for cancer classification using support vector machines. Machine Learning 64:389–422[CrossRef]
27. Aldred MA, Ginn-Pease ME, Morrison CD, Popkie AP, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang SM, Plass C, Eng C 2003 Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res 63:2864–2871[Abstract/Free Full Text]
28. Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm Jr KG, Vinco M, Misek DE, Sanders D, Zhu Z, Ciampi R, Hanash S, Chinnaiyan A, Clifton-Bligh RJ, Robinson BG, Nikiforov YE, Koenig RJ 2006 Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res 12:1983–1993[Abstract/Free Full Text]
29. Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, Zeiger MA, Fahey III TJ 2003 Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 9:1792–1800[Abstract/Free Full Text]
30. Weber F, Shen L, Aldred MA, Morrison CD, Frilling A, Saji M, Schuppert F, Broelsch CE, Ringel MD, Eng C 2005 Genetic classification of benign and malignant thyroid follicular neoplasia based on a 3-gene combination. J Clin Endocrinol Metab 90.:2512–2521
31. Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, Davuluri RV, de la Chapelle A, Eng C 2004 Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22:3531–3539[Abstract/Free Full Text]
32. Chevillard S, Ugolin N, Vielh P, Ory K, Levalois C, Elliott D, Clayman GL, El Naggar AK 2004 Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res 10:6586–6597[Abstract/Free Full Text]
33. Finley DJ, Zhu B, Barden CB, Fahey III TJ 2004 Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 240:425–436[Medline]
34. Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, Talbot M, Caillou B, Levillain JP, Schlumberger M, Bidart JM 2005 Follicular thyroid tumors with the PAX8-PPAR1 rearrangement display characteristic genetic alterations. Am J Pathol 167:223–231[Abstract/Free Full Text]
35. Lubitz CC, Gallagher LA, Finley DJ, Zhu B, Fahey III TJ 2005 Molecular analysis of minimally invasive follicular carcinomas by gene profiling. Surgery 138:1042–1049[CrossRef][Medline]
36. Lui WO, Foukakis T, Liden J, Thoppe SR, Dwight T, Hoog A, Zedenius J, Wallin G, Reimers M, Larsson C 2005 Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR() fusion oncogene. Oncogene 24:1467–1476[CrossRef][Medline]
37. Puskas LG, Juhasz F, Zarva A, Hackler Jr L, Farid NR 2005 Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors. Cell Mol Biol (Noisy-le-grand) 51:177–186[Medline]
38. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, Pellegata NS, de la Chapelle A 2001 Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 98:15044–15049[Abstract/Free Full Text]
39. Lubitz CC, Ugras SK, Kazam JJ, Zhu B, Scognamiglio T, Chen YT, Fahey III TJ 2006 Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. J Mol Diagn 8:490–498[Abstract/Free Full Text]
40. Finley DJ, Arora N, Zhu B, Gallagher L, Fahey III TJ 2004 Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89:3214–3223[Abstract/Free Full Text]
41. Baris O, Savagner F, Nasser V, Loriod B, Granjeaud S, Guyetant S, Franc B, Rodien P, Rohmer V, Bertucci F, Birnbaum D, Malthiery Y, Reynier P, Houlgatte R 2004 Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. J Clin Endocrinol Metab 89:994–1005[Abstract/Free Full Text]
42. Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK, Costourous N 2004 Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 64:2898–2903[Abstract/Free Full Text]
43. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A 2004 Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23:7436–7440[CrossRef][Medline]
44. Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E, Lange D, Pawlaczek A, Szpak S, Gubala E, Swierniak A 2005 Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 65:1587–1597[Abstract/Free Full Text]
45. Yano Y, Uematsu N, Yashiro T, Hara H, Ueno E, Miwa M, Tsujimoto G, Aiyoshi Y, Uchida K 2004 Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin Cancer Res 10:2035–2043[Abstract/Free Full Text]
46. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ, Nikiforov YE 2005 Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24:6646–6656[CrossRef][Medline]
47. Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein R, Singh B 2004 Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64:3780–3789[Abstract/Free Full Text]
48. Eszlinger M, Wiench M, Jarzab B, Krohn K, Beck M, Lauter J, Gubala E, Fujarewicz K, Swierniak A, Paschke R 2006 Meta- and reanalysis of gene expression profiles of hot and cold thyroid nodules and papillary thyroid carcinoma for gene groups. J Clin Endocrinol Metab 91:1934–1942[Abstract/Free Full Text]
49. Stolf BS, Abreu CM, Mahler-Araujo MB, Dellamano M, Martins WK, de Carvalho MB, Curado MP, Diaz JP, Fabri A, Brentani H, Carvalho AF, Soares FA, Kowalski LP, Hirata Jr R, Reis LF 2005 Expression profile of malignant and non-malignant diseases of the thyroid gland reveals altered expression of a common set of genes in goiter and papillary carcinomas. Cancer Lett 227:59–73[CrossRef][Medline]
50. Baris O, Mirebeau-Prunier D, Savagner F, Rodien P, Ballester B, Loriod B, Granjeaud S, Guyetant S, Franc B, Houlgatte R, Reynier P, Malthiery Y 2005 Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma. Oncogene 24:4155–4161[Medline]
51. Eszlinger M, Krohn K, Beck M, Kipling D, Forbes-Robertson S, Lauter J, Tonjes A, Wynford-Thomas D, Paschke R 2006 Comparison of differential gene expression of hot and cold thyroid nodules with primary epithelial cell culture models by investigation of co-regulated gene sets. Biochim Biophys Acta 1763:263–271[Medline]
52. Eszlinger M, Krohn K, Frenzel R, Kropf S, Tonjes A, Paschke R 2004 Gene expression analysis reveals evidence for inactivation of the TGF-ß signaling cascade in autonomously functioning thyroid nodules. Oncogene 23:795–804[CrossRef][Medline]
53. Wattel S, Mircescu H, Venet D, Burniat A, Franc B, Frank S, Andry G, Van Sande J, Rocmans P, Dumont JE, Detours V, Maenhaut C 2005 Gene expression in thyroid autonomous adenomas provides insight into their physiopathology. Oncogene 24:6902–6916[CrossRef][Medline]
54. Eszlinger M, Krohn K, Berger K, Lauter J, Kropf S, Beck M, Fuhrer D, Paschke R 2005 Gene expression analysis reveals evidence for increased expression of cell cycle-associated genes and Gq-protein-protein kinase C signaling in cold thyroid nodules. J Clin Endocrinol Metab 90:1163–1170[Abstract/Free Full Text]
55. Mazzaferri EL, Samaan N 1993 Endocrine tumors. Cambridge, UK: Blackwell; 278
56. Borrello MG, Alberti L, Fischer A, Degl’innocenti D, Ferrario C, Gariboldi M, Marchesi F, Allavena P, Greco A, Collini P, Pilotti S, Cassinelli G, Bressan P, Fugazzola L, Mantovani A, Pierotti MA 2005 Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 102:14825–14830[Abstract/Free Full Text]
57. Detours V, Wattel S, Venet D, Hutsebaut N, Bogdanova T, Tronko MD, Dumont JE, Franc B, Thomas G, Maenhaut C 2005 Absence of a specific radiation signature in post-Chernobyl thyroid cancers. Br J Cancer 92:1545–1552[CrossRef][Medline]
58. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M 2005 The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115:1068–1081[CrossRef][Medline]
59. Hoang-Vu C, Dralle H, Scheumann G, Maenhaut C, Horn R, von zur Muhlen A, Brabant G 1992 Gene expression of differentiation- and dedifferentiation markers in normal and malignant human thyroid tissues. Exp Clin Endocrinol 100:51–56[Medline]
60. Loh KC, Greenspan FS, Dong F, Miller TR, Yeo PP 1999 Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 84:458–463[Abstract/Free Full Text]
61. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE 2005 Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115:94–101[CrossRef][Medline]
62. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–1457[Abstract/Free Full Text]
63. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M 2003 BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578–4580[CrossRef][Medline]
64. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404[Abstract/Free Full Text]
65. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F 2004 BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 89:2414–2420[Abstract/Free Full Text]
66. Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC, Cheng JT 2005 No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 63:461–466[CrossRef][Medline]
67. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, Beck-Peccoz P 2004 BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 61:239–243[CrossRef][Medline]
68. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK 2005 The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 63:588–593[CrossRef][Medline]
69. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE 2006 Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216–222[CrossRef][Medline]
70. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393–4397[Abstract/Free Full Text]
71. Cerutti JM, Delcelo R, Amadei MJ, Nakabashi C, Maciel RM, Peterson B, Shoemaker J, Riggins GJ 2004 A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 113:1234–1242[CrossRef][Medline]
72. Fagin JA 2002 Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 16:903–911[Abstract/Free Full Text]
73. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA 2000 PAX8-PPAR1 fusion oncogene in human thyroid carcinoma [corrected]. Science [Erratum (2000) 289:1474] 289:1357–1360
74. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V 2002 Expression of PAX8-PPAR 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947–3952[Abstract/Free Full Text]
75. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE 2002 PAX8-PPAR rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26:1016–1023[CrossRef][Medline]
76. Cheung L, Messina M, Gill A, Clarkson A, Learoyd D, Delbridge L, Wentworth J, Philips J, Clifton-Bligh R, Robinson BG 2003 Detection of the PAX8-PPAR fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 88:354–357[Abstract/Free Full Text]
77. Gregory PJ, Wang X, Allard BL, Sahin M, Wang XL, Hay ID, Hiddinga HJ, Deshpande SS, Kroll TG, Grebe SK, Eberhardt NL, McIver B 2004 The PAX8/PPAR fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPAR inhibition. Oncogene 23:3634–3641[CrossRef][Medline]
78. French CA, Alexander EK, Cibas ES, Nose V, Laguette J, Faquin W, Garber J, Moore Jr F, Fletcher JA, Larsen PR, Kroll TG 2003 Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 162:1053–1060[Abstract/Free Full Text]
79. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, Kroll TG, Nikiforov YE 2003 RAS point mutations and PAX8-PPAR rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318–2326[Abstract/Free Full Text]
80. Eszlinger M, Krohn K, Kratzsch J, Voigt C, Paschke R 2001 Growth factor expression in cold and hot thyroid nodules. Thyroid 11:125–135[CrossRef][Medline]
81. Gärtner R, Schopohl D, Schaefer S, Dugrillon A, Erdmann A, Toda S, Bechtner G 1997 Regulation of transforming growth factor ß1 messenger ribonucleic acid expression in porcine thyroid follicles in vitro by growth factors, iodine, or -iodolactone. Thyroid 7:633–640[Medline]
82. Voigt C, Holzapfel H, Paschke R 2000 Expression of ß-arrestins in toxic and cold thyroid nodules. FEBS Lett 486:208–212[CrossRef][Medline]
83. Chen W, Kirkbride KC, How T, Nelson CD, Mo J, Frederick JP, Wang XF, Lefkowitz RJ, Blobe GC 2003 Beta-arrestin 2 mediates endocytosis of type III TGF-ß receptor and down-regulation of its signaling. Science 301:1394–1397[Abstract/Free Full Text]
84. Frenzel R, Krohn K, Eszlinger M, Tonjes A, Paschke R 2005 Sialylation of human thyrotropin receptor improves and prolongs its cell-surface expression. Mol Pharmacol 68:1106–1113[Abstract/Free Full Text]
85. Persani L, Lania A, Alberti L, Romoli R, Mantovani G, Filetti S, Spada A, Conti M 2000 Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas. J Clin Endocrinol Metab 85:2872–2878[Abstract/Free Full Text]
86. Voigt C, Holzapfel HP, Meyer S, Paschke R 2004 Increased expression of G-protein-coupled receptor kinases 3 and 4 in hyperfunctioning thyroid nodules. J Endocrinol 182:173–182[Abstract]
87. Eszlinger M, Holzapfel HP, Voigt C, Arkenau C, Paschke R 2004 RGS 2 expression is regulated by TSH and inhibits TSH receptor signaling. Eur J Endocrinol 151:383–390[Abstract]
88. Tonjes A, Miedlich S, Holzapfel HP, Eszlinger M, Arkenau C, Paschke R 2004 Expression of regulators of G protein signaling mRNA is differentially regulated in hot and cold thyroid nodules. Thyroid 14:896–901[CrossRef][Medline]
89. Uyttersprot N, Costagliola S, Dumont JE, Miot F 1999 Requirement for cAMP-response element (CRE) binding protein/CRE modulator transcription factors in thyrotropin-induced proliferation of dog thyroid cells in primary culture. Eur J Biochem 259:370–378[Medline]
90. Finley DJ, Lubitz CC, Wei C, Zhu B, Fahey III TJ 2005 Advancing the molecular diagnosis of thyroid nodules: defining benign lesions by molecular profiling. Thyroid 15:562–568[CrossRef][Medline]
91. Krohn K, Fuhrer D, Bayer Y, Eszlinger M, Brauer V, Neumann S, Paschke R 2005 Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 26:504–524[Abstract/Free Full Text]
92. Krohn K, Emmrich P, Ott N, Paschke R 1999 Increased thyroid epithelial cell proliferation in toxic thyroid nodules. Thyroid 9:241–246[Medline]
93. Krohn K, Stricker I, Emmrich P, Paschke R 2003 Cold thyroid nodules show a marked increase in proliferation markers. Thyroid 13:569–575[CrossRef][Medline]
94. Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW, Harris PE 1999 Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 50:529–535[CrossRef][Medline]
95. Krohn K, Reske A, Ackermann F, Muller A, Paschke R 2001 Ras mutations are rare in solitary cold and toxic thyroid nodules. Clin Endocrinol (Oxf) 55:241–248[CrossRef][Medline]
96. Gire V, Wynford-Thomas D 2000 RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. Oncogene 19:737–744[CrossRef][Medline]
97. Bachrach LK, Eggo MC, Mak WW, Burrow GN 1985 Phorbol esters stimulate growth and inhibit differentiation in cultured thyroid cells. Endocrinology 116:1603–1609[Abstract/Free Full Text]
98. Haye B, Aublin JL, Champion S, Lambert B, Jacquemin C 1985 Tetradecanoyl phorbol-13-acetate counteracts the responsiveness of cultured thyroid cells to thyrotropin. Biochem Pharmacol 34:3795–3802[CrossRef][Medline]
99. Roger PP, Reuse S, Servais P, Van Heuverswyn B, Dumont JE 1986 Stimulation of cell proliferation and inhibition of differentiation expression by tumor-promoting phorbol esters in dog thyroid cells in primary culture. Cancer Res 46:898–906[Abstract/Free Full Text]
100. Takasu N, Shimizu Y, Yamada T 1987 Tumour promoter 12-O-tetradecanoylphorbol 13-acetate and epidermal growth factor stimulate proliferation and inhibit differentiation of porcine thyroid cells in primary culture. J Endocrinol 113:485–487[Abstract/Free Full Text]
101. Vassart G, Dumont JE 1992 The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 13:596–611[Abstract/Free Full Text]
102. Van Herle AJ, Agatep ML, Padua III DN, Totanes TL, Canlapan DV, Van Herle HM, Juillard GJ 1990 Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro. J Clin Endocrinol Metab 71:755–763[Abstract/Free Full Text]
103. Schmutzler C, Brtko J, Bienert K, Kohrle J 1996 Effects of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived therefrom. Exp Clin Endocrinol Diabetes 104(Suppl 4):16–19
104. Schreck R, Schnieders F, Schmutzler C, Kohrle J 1994 Retinoids stimulate type I iodothyronine 5'-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 79:791–798[Abstract]
105. Donovan M, Olofsson B, Gustafson AL, Dencker L, Eriksson U 1995 The cellular retinoic acid-binding proteins. J Steroid Biochem Mol Biol 53:459–465[CrossRef][Medline]
106. Aogi K, Kitahara K, Buley I, Backdahl M, Tahara H, Sugino T, Tarin D, Goodison S 1998 Telomerase activity in lesions of the thyroid: application to diagnosis of clinical samples including fine-needle aspirates. Clin Cancer Res 4:1965–1970[Abstract]
107. Bernet VJ, Anderson J, Vaishnav Y, Solomon B, Adair CF, Saji M, Burman KD, Burch HB, Ringel MD 2002 Determination of galectin-3 messenger ribonucleic acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 87:4792–4796[Abstract/Free Full Text]
108. Casey MB, Lohse CM, Lloyd RV 2003 Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol 14:55–60[CrossRef][Medline]
109. Haugen BR, Nawaz S, Markham N, Hashizumi T, Shroyer AL, Werness B, Shroyer KR 1997 Telomerase activity in benign and malignant thyroid tumors. Thyroid 7:337–342[Medline]
110. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A, Kubo T 1999 Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85:2475–2484[CrossRef][Medline]
111. Ippolito A, Vella V, La Rosa GL, Pellegriti G, Vigneri R, Belfiore A 2001 Immunostaining for Met/HGF receptor may be useful to identify malignancies in thyroid lesions classified suspicious at fine-needle aspiration biopsy. Thyroid 11:783–787[CrossRef][Medline]
112. Mase T, Funahashi H, Koshikawa T, Imai T, Nara Y, Tanaka Y, Nakao A 2003 HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J 50:173–177[CrossRef][Medline]
113. Raphael SJ 2002 The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia. Endocr Pathol 13:301–311[CrossRef][Medline]
114. Sack MJ, Astengo-Osuna C, Lin BT, Battifora H, LiVolsi VA 1997 HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol 10:668–674[Medline]
115. Saggiorato E, Cappia S, De Giuli P, Mussa A, Pancani G, Caraci P, Angeli A, Orlandi F 2001 Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 86:5152–5158[Abstract/Free Full Text]
116. Kholova I, Ryska A, Ludvikova M, Cap J, Pecen L 2003 Dipeptidyl peptidase IV expression in thyroid cytology: retrospective histologically confirmed study. Cytopathology 14:27–31[CrossRef][Medline]
117. Giannini R, Faviana P, Cavinato T, Elisei R, Pacini F, Berti P, Fontanini G, Ugolini C, Camacci T, De Ieso K, Miccoli P, Pinchera A, Basolo F 2003 Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid 13:765–770[CrossRef][Medline]
118. Papotti M, Rodriguez J, De Pompa R, Bartolazzi A, Rosai J 2005 Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 18:541–546[CrossRef][Medline]
119. Prasad ML, Huang Y, Pellegata NS, de la Chapelle A, Kloos RT 2004 Hashimoto’s thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology 45:39–46[CrossRef][Medline]
120. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M 2005 Characterization of thyroid ‘follicular neoplasms’ in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer 12:305–317[Abstract/Free Full Text]
121. Takano T, Miyauchi A, Matsuzuka F, Kuma K, Amino N 2000 Expression of oncofetal fibronectin messenger ribonucleic acid in fibroblasts in the thyroid: a possible cause of false positive results in molecular-based diagnosis of thyroid carcinomas. J Clin Endocrinol Metab 85:765–768[Abstract/Free Full Text]
122. Grutzmann R, Boriss H, Ammerpohl O, Luttges J, Kalthoff H, Schackert HK, Kloppel G, Saeger HD, Pilarsky C 2005 Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene 24:5079–5088[CrossRef][Medline]
123. Kebebew E, Peng M, Reiff E, McMillan A 2006 Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer 106:2592–2597[CrossRef][Medline]
124. Venet D, Pecasse F, Maenhaut C, Bersini H 2001 Separation of samples into their constituents using gene expression data. Bioinformatics 17(Suppl 1):S279–S287
125. Lubitz CC, Fahey III TJ 2006 Gene expression profiling of thyroid tumors—clinical applicability. Nat Clin Pract Endocrinol Metab 2:472–473[CrossRef][Medline]
126. Tan PK, Downey TJ, Spitznagel Jr EL, Xu P, Fu D, Dimitrov DS, Lempicki RA, Raaka BM, Cam MC 2003 Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res 31:5676–5684[Abstract/Free Full Text]
127. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO 2000 Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24:227–235[CrossRef][Medline]
128. Kuo WP, Jenssen TK, Butte AJ, Ohno-Machado L, Kohane IS 2002 Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics 18:405–412[Abstract/Free Full Text]
129. Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J 2005 Independence and reproducibility across microarray platforms. Nat Methods 2:337–344[CrossRef][Medline]
130. Bammler T, Beyer RP, Bhattacharya S, Boorman GA, Boyles A, Bradford BU, Bumgarner RE, Bushel PR, Chaturvedi K, Choi D, Cunningham ML, Deng S, Dressman HK, Fannin RD, Farin FM, Freedman JH, Fry RC, Harper A, Humble MC, Hurban P, Kavanagh TJ, Kaufmann WK, Kerr KF, Jing L, Lapidus JA, Lasarev MR, Li J, Li YJ, Lobenhofer EK, Lu X, Malek RL, Milton S, Nagalla SR, O’Malley JP, Palmer VS, Pattee P, Paules RS, Perou CM, Phillips K, Qin LX, Qiu Y, Quigley SD, Rodland M, Rusyn I, Samson LD, Schwartz DA, Shi Y, Shin JL, Sieber SO, Slifer S, Speer MC, Spencer PS, Sproles DI, Swenberg JA, Suk WA, Sullivan RC, Tian R, Tennant RW, Todd SA, Tucker CJ, Van Houten B, Weis BK, Xuan S, Zarbl H 2005 Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods 2:351–356[CrossRef][Medline]
131. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, Gabrielson E, Garcia JG, Geoghegan J, Germino G, Griffin C, Hilmer SC, Hoffman E, Jedlicka AE, Kawasaki E, Martinez-Murillo F, Morsberger L, Lee H, Petersen D, Quackenbush J, Scott A, Wilson M, Yang Y, Ye SQ, Yu W 2005 Multiple-laboratory comparison of microarray platforms. Nat Methods 2:345–350[CrossRef][Medline]
132. Griffith OL, Melck A, Jones SJ, Wiseman SM 2006 Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol 24:5043–5051[Abstract/Free Full Text]
133. Bruno R, Ferretti E, Tosi E, Arturi F, Giannasio P, Mattei T, Scipioni A, Presta I, Morisi R, Gulino A, Filetti S, Russo D 2005 Modulation of thyroid-specific gene expression in normal and nodular human thyroid tissues from adults: an in vivo effect of thyrotropin. J Clin Endocrinol Metab 90:5692–5697[Abstract/Free Full Text]
134. Eszlinger M, Krohn K, Toenjes A, Läuter J, Paschke R 2007 Variability of gene expression of "normal" thyroid tissue. Exp Clin Endocrinol Diabetes 115(Suppl 1):8 (Abstract)
135. Gharib H 1997 Changing concepts in the diagnosis and management of thyroid nodules. Endocrinol Metab Clin North Am 26:777–800[CrossRef][Medline]
136. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O 2001 Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357:1644–1650[CrossRef][Medline]
137. de Micco C, Ruf J, Chrestian MA, Gros N, Henry JF, Carayon P 1991 Immunohistochemical study of thyroid peroxidase in normal, hyperplastic, and neoplastic human thyroid tissues. Cancer 67:3036–3041[CrossRef][Medline]
138. Fagin JA 2002 Perspective: lessons learned from molecular genetic studies of thyroid cancer–insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology 143:2025–2028[Free Full Text]
139. Gimm O 2001 Thyroid cancer. Cancer Lett 163:143–156[CrossRef][Medline]
140. Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, Sidransky D, Westra WH 2004 Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 10:2761–2765[Abstract/Free Full Text]
141. Jin L, Sebo TJ, Nakamura N, Qian X, Oliveira A, Majerus JA, Johnson MR, Lloyd RV 2006 BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 15:136–143[CrossRef][Medline]
142. Rowe LM, Bentz BM, Bentz JM 2006 Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 3:10[CrossRef][Medline]
143. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F, Santoro M 2004 Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 89:5175–5180[Abstract/Free Full Text]
144. Malamos B, Koutras DA, Kostamis P, Rigopoulos GA, Zerefos NS, Yataganas XA 1967 Endemic goitre in Greece: a study of 379 twin pairs. J Med Genet 4:16–18[Free Full Text]
145. Hadjidakis SG, Koutras DA, Daikos GK 1964 Endemic goitre in Greece: family studies. J Med Genet 38:82–87[Medline]
146. Bignell GR, Canzian F, Shayeghi M, Stark M, Shugart YY, Biggs P, Mangion J, Hamoudi R, Rosenblatt J, Buu P, Sun S, Stoffer SS, Goldgar DE, Romeo G, Houlston RS, Narod SA, Stratton MR, Foulkes WD 1997 Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet 61:1123–1130[CrossRef][Medline]
147. Capon F, Tacconelli A, Giardina E, Sciacchitano S, Bruno R, Tassi V, Trischitta V, Filetti S, Dallapiccola B, Novelli G 2000 Mapping a dominant form of multinodular goiter to chromosome Xp22. Am J Hum Genet 67:1004–1007[CrossRef][Medline]
148. Neumann S, Willgerodt H, Ackermann F, Reske A, Jung M, Reis A, Paschke R 1999 Linkage of familial euthyroid goiter to the multinodular goiter-1 locus and exclusion of the candidate genes thyroglobulin, thyroperoxidase, and Na+/I– symporter. J Clin Endocrinol Metab 84:3750–3756[Abstract/Free Full Text]
149. Bayer Y, Neumann S, Meyer B, Ruschendorf F, Reske A, Brix T, Hegedus L, Langer P, Nurnberg P, Paschke R 2004 Genome-wide linkage analysis reveals evidence for four new susceptibility loci for familial euthyroid goiter. J Clin Endocrinol Metab 89:4044–4052[Abstract/Free Full Text]
150. Bottcher Y, Eszlinger M, Tonjes A, Paschke R 2005 The genetics of euthyroid familial goiter. Trends Endocrinol Metab 16:314–319[CrossRef][Medline]
151. Rodrigues RF, Roque L, Rosa-Santos J, Cid O, Soares J 2004 Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas. Br J Cancer 90:492–496[CrossRef][Medline]
152. Roque L, Rodrigues R, Pinto A, Moura-Nunes V, Soares J 2003 Chromosome imbalances in thyroid follicular neoplasms: a comparison between follicular adenomas and carcinomas. Genes Chromosomes Cancer 36:292–302[CrossRef][Medline]
153. Castro P, Eknaes M, Teixeira MR, Danielsen HE, Soares P, Lothe RA, Sobrinho-Simoes M 2005 Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. J Pathol 206:305–311[CrossRef][Medline]
154. Wreesmann VB, Ghossein RA, Hezel M, Banerjee D, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B 2004 Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity. Genes Chromosomes Cancer 40:355–364[CrossRef][Medline]
155. Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H 2003 Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 9:68–75[Abstract/Free Full Text]
156. Prasad ML, Pellegata NS, Kloos RT, Barbacioru C, Huang Y, de la Chapelle A 2004 CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray-based study. Thyroid 14:169–175[CrossRef][Medline]
157. Zou M, Famulski KS, Parhar RS, Baitei E, Al Mohanna FA, Farid NR, Shi Y 2004 Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab 89:6146–6154[Abstract/Free Full Text]
158. Chen KT, Lin JD, Chao TC, Hsueh C, Chang CA, Weng HF, Chan EC 2001 Identifying differentially expressed genes associated with metastasis of follicular thyroid cancer by cDNA expression array. Thyroid 11:41–46[CrossRef][Medline]
159. Hamada A, Mankovskaya S, Saenko V, Rogounovitch T, Mine M, Namba H, Nakashima M, Demidchik Y, Demidchik E, Yamashita S 2005 Diagnostic usefulness of PCR profiling of the differentially expressed marker genes in thyroid papillary carcinomas. Cancer Lett 224:289–301[CrossRef][Medline]
160. Takano T, Hasegawa Y, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K, Hayashi N, Nakamori S, Amino N 2002 Quantitative analysis of osteonectin mRNA in thyroid carcinomas. Endocr J 49:511–516[CrossRef][Medline]
161. Takano T, Miyauchi A, Yoshida H, Kuma K, Amino N 2004 High-throughput differential screening of mRNAs by serial analysis of gene expression: decreased expression of trefoil factor 3 mRNA in thyroid follicular carcinomas. Br J Cancer 90:1600–1605[CrossRef][Medline]
162. Jacques C, Baris O, Prunier-Mirebeau D, Savagner F, Rodien P, Rohmer V, Franc B, Guyetant S, Malthiery Y, Reynier P 2005 Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J Clin Endocrinol Metab 90:2314–2320[Abstract/Free Full Text]
163. Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, Sharma V 2004 Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 89:272–280[Abstract/Free Full Text]
164. Aksoy M, Giles Y, Kapran Y, Terzioglu T, Tezelman S 2005 Expression of bcl-2 in papillary thyroid cancers and its prognostic value. Acta Chir Belg 105:644–648[Medline]

This article has been cited by other articles:

				R. C Smallridge, L. A Marlow, and J. A Copland Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies Endocr. Relat. Cancer, March 1, 2009; 16(1): 17 - 44. [Abstract] [Full Text] [PDF]

				M. Eszlinger, K. Krohn, S. Hauptmann, H. Dralle, T. J. Giordano, and R. Paschke Perspectives for Improved and More Accurate Classification of Thyroid Epithelial Tumors J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3286 - 3294. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eszlinger, M. Articles by Paschke, R. Search for Related Content PubMed PubMed Citation Articles by Eszlinger, M. Articles by Paschke, R.